Lexaria's Human Study GLP-1-H26-7 Reaches Full Enrollment and Continues Dosing on ScheduleAccesswire · 5 days ago
Lexaria's Human Study GLP-1-H26-7 Reaches Full Enrollment and Continues Dosing on ScheduleTheNewswire · 5 days ago
Lexaria Announces Results from Animal Study GLP-1-A26-1Accesswire · Oct 15, 2026
Lexaria Announces Results From Animal Study GLP-1-A26-1TheNewswire · Oct 15, 2026
GLP-1 Weight-Loss/Diabetes Industries Continue Transition to Oral MedicationsTheNewswire · Oct 6, 2026
GLP-1 Weight-Loss/Diabetes Industries Continue Transition to Oral MedicationsAccesswire · Oct 6, 2026Lexaria Bioscience Corp. is a biotechnology company focused on advanced drug delivery. Its proprietary and patented DehydraTECH technology is designed to significantly improve the oral delivery of active pharmaceutical ingredients, enhancing their absorption into the bloodstream. This innovative platform has shown impressive results, boosting the bioavailability of compounds such as cannabinoids and nicotine by 5 to 10 times, and in some cannabinoid applications, by as much as 27 times, when compared to standard formulations.
| Date | Est. | Actual | |
|---|---|---|---|
| Jul 13, 2026 | -$0.90 | -$1.20 | Miss |
| Apr 13, 2026 | -$1.05 | -$0.90 | Beat |
| Jan 13, 2026 | -$1.95 | -$1.05 | Beat |
| Nov 26, 2025 | -$2.40 | -$2.10 | Beat |
| Jul 14, 2025 | -$2.25 | -$3.15 | Miss |
| Apr 14, 2025 | -$2.40 | -$2.25 | Beat |